Table 1. Series of patients.

No.: number; M: male; F: female; IMN: intramedullary nail; ASA-PS: American Society of Anesthesiologists physical status; AWD: alive with disease; DOD: dead of disease.

No.	Age	Sex	Cite	Primary	Surgical treatment	Adjuvant therapy	Mirel’s score	Katagiri’s score	ASA-PS	Outcome	MSTS score	Follow-up periods (months)
1	75	M	Radius	Renal	-(RT)	-	9	6	1	AWD	27	4
2	83	F	Humerus	Liver	IMN	Chemotherapy (sorafenib)	9	7	2	DOD	27	20
3	56	M	Humerus	Lung	IMN	Chemotherapy (cisplatin and carboplatin)	9	6	2	AWD	26	1
4	70	M	Humerus	Renal	Double plating	Chemotherapy (sunitinib)	9	6	2	AWD	19	19
5	74	M	Humerus	Hodgkin’s lymphoma	IMN	Chemotherapy (Adriamycin, bleomycin, vinblastine, dacarbazine)	9	5	2	AWD	27	5
6	46	F	Humerus	Multiple myeloma	IMN	Chemotherapy (bortezomib)	9	6	2	AWD	28	6
7	77	F	Radius	Plasmacytoma	Plating	Chemotherapy (bortezomib)	9	3	1	AWD	25	2
8	74	M	Humerus	Liver	IMN	Chemotherapy (lenvatinib)	9	8	2	DOD	27	4
9	65	M	Humerus	Liver	IMN	Chemotherapy (lenvatinib)	9	4	2	AWD	25	3
10	73	M	Humerus	Lung	IMN	Chemotherapy (gefitinib)	9	4	1	DOD	25	16